Further, addition of FANA-CD39-AS oligonucleotides to Treg boosts the suppressive function of these cells in vitro in samples from Crohn’s disease patients, where high levels of CD39-AS RNA are present, and in vivo, where injection of FANA-CD39-AS oligonucleotide-treated human Treg results in beneficial effects in a model of TNBS colitis in NOD/scid/gamma recipients reconstituted with human CD4+ lymphocytes. This evidence concerns the gene ENTPD1 and Crohn disease.